Bausch + Lomb (NYSE:BLCO) stock drops as the company lowers its growth outlook after lower than expected Q1 2025 financials.

Eyecare company Bausch + Lomb (NYSE:BLCO) in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, ...

Bausch + Lomb issued the recall after the company received reports of toxic anterior segment syndrome, or an inflammatory reaction inside the eye.

The eye health company Bausch + Lomb announced on Monday that it is recalling several of its intraocular lenses due to safety concerns. The company said it was recalling several of its enVista ...

Bausch + Lomb will return its enVista intraocular lenses to market following a voluntary recall in March after discovering they had certain production and material issues.

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns. On Thursday ...

(RTTNews) - Eye health firm Bausch + Lomb Corp. has recalled certain intraocular lenses or IOLs on its enVista platform following reports of complications, the cause of which could not immediately ...

Bausch + Lomb is committed to sustainable practices that support people and communities worldwide.

With a nearly 170-year history dedicated to vision care and eye health innovation, Bausch + Lomb (NYSE:BLCO) develops and manufactures a comprehensive range of eye health products including ...